Hongqi Pharmaceutical
HONGQI PHARMACEUTICAL
Cherish life, pay attention to health.
CHERISH LIFE CARE ABOUT HEALTH
Depth (Part 2): Guo Guangchang is holding hands with the originator of surgical robots in the world. Behind it is a big chess game that goes deep into the entire industry chain of AI, precision medicine, and health
Category:
Trade info
Author:
Source:
Add time:2016-12-19 21:41
In the previous article, the editor has deeply interpreted Fosun Pharma’s recent big moves: holding hands with Intuitive Surgical, the originator of the world's surgical robots, with the purpose of "Made in China, joint research and development, and global sales". Overcome the worldwide problem of early diagnosis of lung cancer.
Please click the following link to review the full text of (Part 1):
Depth (Part 1): Guo Guangchang is holding hands with the originator of surgical robots in the world. Behind it is a big chess game that goes deep into the entire industry chain of AI, precision medicine, and health.
(Part 1)
1. Keyword 1: Intuitive Surgical
2. Keyword 2: Early diagnosis and treatment of lung cancer
3. Keyword three: R&D, production and sales
4. Keyword four: AI artificial intelligence
(Part 2)
5. Medical device sector: world-class products lead growth
6. Fosun Pharma Medical's entire industrial chain picture
7. Fosun General Health “Ecosphere”
Today, the editor will take you to continue to interpret the "big chess game" reflected by Fosun Health, Fosun Pharma in the medical device sector, and even the entire medical industry chain.
Medical device sector: world-class products lead growth
According to the 2016 semi-annual report of Fosun Pharma, its operating income in the first half of 2016 was nearly RMB 7 billion, an increase of 17.15% over the same period in 2015, and the net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses exceeded RMB 11. 100 million yuan, an increase of 26.80% over the same period in 2015.
Among them, the performance of the medical equipment sector is outstanding. Da Vinci surgical robots have reached about 8,000 operations in mainland China and Hong Kong, an increase of about 49% over the same period in 2015; Alma Lasers, which focuses on medical laser beauty products, continues to accelerate Open up the global market, and focus on emerging markets such as China and India, further strengthen the development of new products, especially medical treatment devices, and expand the product line to the clinical treatment field. During the first half of 2016, a total of 5 new EU CE certifications were obtained; in addition; , The dental digital product line has become a new growth point for Fosun Pharma’s medical device business, achieving a 175% growth in the first half of 2016 compared to the same period in 2015.
From the perspective of Fosun Pharma's layout of DaVinci Robotics, Alma Lasers, and dental digital product lines, The layout of its equipment segment is driven by innovation, connecting global resources, and focusing on the Chinese market. In terms of performance figures, the medical device sector has become one of the engines of Fosun Pharma's rapid development.
The three series of products mentioned above are all at the forefront of the world's technological innovation.
The Da Vinci robot has been detailed in the previous article, and it is a "originator" enterprise in this field.
Alma Lasers, controlled by Fosun Pharma, is the world's leading supplier of energy medical beauty treatment systems. It is also an enterprise that pays special attention to innovation and research and development. In addition, its new product launch speed in the laser medical device business ranks among the world's forefront, with an advanced technology platform.
Alma Lasers laser medical beauty products
The digital product line of the dental business based on the Internet and C2M thinking is also expected. As early as 2010, Fosun Dental Division and the world's leading German BEGO company jointly established Shanghai Fosun-Germany BEGO CAD/ The CAM Dental Technology Center introduces the most advanced digital equipment in the world to meet the highest standards of customers.
Fosun Dental's new digital product line
Chen Qiyu revealed Fosun Pharma’s layout ideas in an interview: “The Da Vinci Robotics business was cultivated by us over a period of 10 years. It can be said that the previous seven or eight years were the investment period. The Da Vinci product was brought to China. Through continuous education and training of excellent Chinese doctors, continuous dissemination in China, and establishment of the Da Vinci brand, it has today's preliminary situation. ”
This passage is a good interpretation of the long-term perspective of Fosun Pharma, aiming at the world’s top technologies, patience and perseverance in fine cultivation and operation, and finally ushering in the explosive growth of the layout. "In fact, we are very clear." strong>In the future, innovation is at the core of Fosun Pharma’s territory, that is, any new thing I make must be based on innovation, whether it is a robot or the laser medical equipment we are making now, it must be based on such a positioning Advancing. I feel that Fosun Pharma has not done enough in the field of medical devices in the past. Now we have taken corresponding measures to increase the research and development of innovative medical devices and global search goals. We are very concerned about two points in medical equipment: one is the marketing of advanced technology medical equipment and medical products in the Chinese market. We must grasp this, and use this end to understand the trends of the industry in real time; in addition, we must look for robots like this. After finding innovative products, we must resolutely seek cooperation. ”
At present, China's medical device field is in a period of rapid development. According to Chairman Zhao Zilin's introduction: “In recent years, the market size of medical equipment in my country has grown rapidly, reaching 480 billion yuan by 2015. It is expected that the market size will exceed 800 billion in 2020, and strive to become a powerful country in the development of medical equipment by 2025. The growth rate of our medical equipment is much higher than that of my country's GDP, with an annual growth rate of 15 to 20%. ”
Under such a general environment, the products that Fosun Pharma has cultivated and cultivated for a long time in the early stage are expected to usher in a harvest period.
Innovatively cover the entire medical industry chain and build a first-class enterprise in the global mainstream health market
The rapid growth of the medical device sector is expected, but from the perspective of Fosun Pharma as a whole, the core is pharmaceutical manufacturing and research and development. According to its 2016 semi-annual report, the pharmaceutical manufacturing and research and development sector accounted for nearly 70 % Of revenue accounted for. Fosun Pharma was founded in 1994 and has now developed into a comprehensive and leading healthcare industry group with business covering pharmaceutical manufacturing and R&D, medical services, medical diagnosis and medical devices, and pharmaceutical distribution and retail.
In the words of Chairman Chen Qiyu: “Fosun Pharmaceutical's business is very unique in all the medical and health industries in China, covering a wide range of strategic business links in the entire medical industry. Our pharmaceutical business is in a leading position in China's pharmaceutical industry, the medical device diagnosis industry is developing rapidly, and the medical service industry is also on a rapid development track. In addition, Sinopharm began to cooperate with China National Pharmaceutical Group to establish Sinopharm Holdings in 2003. Today, Sinopharm has become a listed company with more than RMB 200 billion in receivables. In the past ten years, we have continuously increased our investment in innovation and research and development. Innovation is not only the driving force of our business, but also the most important task of Fosun Pharma’s social responsibility. We publish a social responsibility report every year, and we always rank first in the social responsibility of China's pharmaceutical industry. As a leading medical and health company in China, we believe that the most important social responsibility is to innovate, to provide our Chinese patients and patients around the world with better medical solutions and more affordable medical solutions. In the past ten years, our investment in the pharmaceutical industry has continued to increase. Today, we are one of the companies with the largest R&D investment in China's pharmaceutical industry. In the next few years, we will continue to increase pharmaceutical R&D investment. ”
In fact, when I look closely at Fosun Pharma, I see that it has a very solid R&D foundation and industry-leading R&D investment. It is a company that has frequent highlights along the entire chain of the medical industry chain and penetrates into the industry.
Take a careful inventory. In the pharmaceutical manufacturing and R&D sector, Fosun Pharma has platforms such as Fuhong Henlius, Xingtai, Chongqing Medical Engineering Institute, and Fosun Pharma. Using global resources, Shanghai, Chongqing, Taipei, and San Francisco in the United States. The 24-hour joint research and development model focuses on the research and development of small molecule chemical innovative drugs, macromolecular biosimilar drugs, high-value generic drugs and specialty preparations.
Among them, Henlius is the leading monoclonal antibody platform in China. Just recently, in the field of biosimilar drugs, its self-developed injection-use recombinant anti-HER2 humanized monoclonal antibody breast cancer new drug has completed Phase I Clinical research, and officially launched Phase III clinical trials; in the field of innovative monoclonal antibodies, its first innovative bio-modified monoclonal antibody HLX07 was approved for clinical trials for colorectal cancer and other solid cancer indications. So far, The new drug has been clinically approved in China, Taiwan and the United States, and has achieved the international development strategy of research and development products through the three registration applications. In addition, Henlius has also added two innovative monoclonal antibodies through authorized cooperation with internationally renowned biomedical companies to further enhance its competitiveness in the anti-tumor field. This innovation team led by outstanding scientists has become a jewel in the field of Fosun Pharma's biopharmaceutical innovation.
The picture shows the team of scientists led by Fuhong Henlius CEO Liu Shigao
In general, as of the first half of 2016, Fosun Pharma Group has been developing 172 new drugs, generic drugs, biosimilar drugs and vaccines; there are 5 monoclonal antibody varieties and 2 small molecule chemical innovative drugs in Or get permission to enter the clinical research phase. Through the talent innovation mechanism, Fosun Pharma cooperates with entrepreneurial scientists and outstanding teams at home and abroad to form a "community of value", which has gathered a large number of scientists and high-tech talent groups from home and abroad. At present, Fosun Pharma Group has more than 900 R&D personnel, forming a solid talent and development foundation.
Chairman Chen Qiyu introduced: "Fosun Pharma has been in the process of overall transformation in the past two years. First, we are now an innovative organization, firmly taking technological innovation as the driving force to carry out organizational changes. So first of all, we have done a lot in the pharmaceutical business. After 10 years, we have formed a very clear innovation investment route in the pharmaceutical business. This year, we have become one of the companies with the largest R&D investment in China's pharmaceutical industry. The second more important feature is that our innovation model is ‘China+US’. The United States is the source of innovative technology and innovative talent teams, while China is a very good low-cost, fast-innovating place. Many of the highly integrated innovative technologies come from the United States, but in China, it can be scaled up quickly at low cost. We have a large number of technicians, a large number of R&D scientists, and a large amount of clinical data. This is our advantage. What we have to do in terms of innovation is to increase investment, from a global perspective, and strive for the largest share of the global market. ”
In the pharmaceutical distribution and retail sector, after more than 10 years of development, Sinopharm Holdings, in which Fosun Pharma’s equity investment, has become China’s largest distributor of pharmaceuticals and healthcare products and a leading supply chain service provider, owns and operates China The largest pharmaceutical distribution and distribution network. As of the first half of 2016, Sinopharm’s distribution network has covered 31 provinces, autonomous regions, and municipalities in China; its direct customers have reached 13,841 (only refers to tiered hospitals, including 1,880 of the largest and highest level tertiary hospitals); retail The network of pharmacies has further expanded, and its subsidiary Guoda Pharmacy has 3,268 retail pharmacies. Fosun Pharma and Sinopharm Group have always maintained close cooperation to give full play to the synergy between the two parties.
Strong distribution system of Sinopharm Holdings
In the medical service sector, Fosun Pharma is the "first mover" of social capital in medical services. As of the first half of 2016, Fosun Pharma has 3,018 approved beds in Chancheng Hospital, Jimin Hospital, Guangji Hospital, Zhongwu Hospital and Wenzhou Geriatrics Hospital.
At present, Fosun Pharma continues to strengthen the strategic layout of the medical service business that combines high-end medical care in developed coastal cities, specialists in second and third tier cities, and general hospitals, to build regional medical centers and a large health industry chain, and seek cooperation Local large-scale state-owned enterprises, public hospitals, and university hospitals are cooperating to accelerate the development of Internet medical services, and continue to increase business scale and profitability.
Recently, the overall reorganization of the medical institutions affiliated to Xu Mining Group by Xu Mining Group, Fosun Pharmaceutical, and Taikang Insurance Group has been announced, and the reorganized Huaihai Hospital Management Group Co., Ltd. was officially inaugurated. This mixed-ownership reorganization not only innovated the ownership form of hospitals in the region, but also effectively introduced a competition mechanism for private enterprises. It will also provide a new model of medical services to the masses in the Huaihai Economic Zone. At the same time, its reorganization method also created a precedent for the nationwide state-owned hospital system reform.
Fosun Pharmaceutical is the “first mover” of social capital in medical care
In addition, Fosun Pharma also continues to actively support and promote the development and deployment of the U.S.-China Mutual Benefit’s leading high-end medical service brand “United Family” hospital and clinic network. In the first half of 2016, "United Family" Hospital continued to maintain its brand appeal and leading position in the high-end medical field in core cities such as Beijing, Tianjin, and Shanghai. Guangzhou United Family Hospital is also stepping up its construction.
It can be seen that Fosun Pharma’s strategy is to build industry-leading products and platforms around all links of the medical industry chain. Through long-term cultivation of high-quality projects, continuous investment in innovation and R&D will usher in when the time is right. Explosive growth.
At the same time, the synergy benefited from the integration of the integrated industrial chain is also considerable. For example, the development of Alma Lasers in China is a typical case of Fosun Pharma’s deep integration of high-quality foreign products. At present, Alma Lasers is located in Chancheng Hospital, Fosun Pharma’s medical service systems such as United Family have set up "laser medical beauty centers", in-depth contact with precise customers, and significant synergies. It is believed that the newly established joint venture company announced by Fosun Pharma and Intuitive Surgical this time will surely be deeply integrated with other businesses of Fosun Pharma in the future.
From the perspective of Fosun Pharma’s current layout, its ambition to build a “first-class enterprise in the global mainstream health market” is no longer a slogan, but already has a solid industrial foundation.
The deepest part of Fosun’s big game is to build a “Fosun Big Health Ecosystem”
Fosun Pharmaceutical's "full medical industry chain" has a grand picture, but in the eyes of Fosun Group Chairman Guo Guangchang, who has "philosophy" thinking, there is clearly a bigger game.
Still at the press conference on December 10, Guo Guangchang, Chairman of Fosun Group, said in his speech: "Fosun Pharmaceutical is developing very well now, and the annual profit is not something I worry about. I pay attention to it every year. What I want is to speed up R&D investment and make me something that can represent the heights of China and the world. For example, I require a high degree of accuracy in the treatment of cancer and accurate surgical treatment. This height is very important to Fosun. I personally predict that in 5 to 6 years, cancer will be a chronic disease. Just like pneumonia before, it will gradually become a chronic disease and it can be resolved. After the surgery is accurate, the operation is not so complicated. After the operation, drink a glass of water and you can leave. The technological development in this area is very exciting. ”
Currently, "Fosun Health" is taking an innovative path that takes China as the target market and grafts global resources. Focusing on the background of precision medicine and the advancement of artificial intelligence, combined with the technology of developed countries including the United States and the Chinese market, it focuses on therapeutic areas including oncology drugs, tumor diagnosis and treatment.
In addition, Fosun General Health also embraces the concept of "not only curing diseases, but also preventing diseases", allowing more than just medical servicesBeing able to serve patients can also be expanded to provide health management services for the vast number of sub-healthy and healthy people, and use high-quality medical technology to provide personalized health services for the general public.
Conclusion
In October 2016, the Chinese government issued the "“Healthy China 2030” Plan Outline", with the theme of “building and sharing, health for all", and proposed a new path and new goals for building a healthy China. By 2030, the scale of China's health industry will be significantly expanded. In the document, the concept of healthy China has been elevated to an unprecedented height for the first time. With this as a starting point, relevant supporting policies will be introduced one after another in the future, and the healthy China industry will usher in a new round of development opportunities. It is estimated that by 2020, the scale of the large-scale health industry, including medicine and health, medical services, health services, pensions, and medical equipment, is expected to achieve substantial growth.
According to the laws of the global market, with the emergence of such a huge market, a large-scale listed company in the healthcare industry with local and global influence in the industry will surely be formed.
Can Fosun Health “Ecosphere” with Fosun Pharma at its core become China’s “J&J”? let us wait and see!
